Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7806295 | 0.87 | CTSS (0.54) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL1139049 | 0.81 | CTSS (0.84) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL3799114 | 0.78 | CTSS (0.68) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL27868136 | 0.78 | CTSS (0.68) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL1139645 | 0.78 | CTSS (0.68) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL7804457 | 0.77 | CTSS (0.68) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL1139296 | 0.76 | CTSS (0.66) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL27851182 | 0.76 | CTSS (0.66) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL15678492 | 0.76 | CTSS (0.74) | CTSSCTSLCTSBCTSKHTT | |
| SCHEMBL7809642 | 0.75 | CTSS (0.69) | CTSSCTSLCTSBCTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010142650-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | CTSS 2367/4885CTSL 2122/4885CTSB 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.